This health economic evaluation demonstrates that in patients with moderately to severely active ulcerative colitis in Canada, conventional therapy offers the most cost-effective therapeutic option in the overall population followed by vedolizumab subcutaneous (SC), which is cost effective compared with advanced therapies (adalimumab SC, infliximab intravenous, golimumab SC, low-dose tofacitinib, ustekinumab SC, and vedolizumab intravenous), showing either dominance or a very low incremental cost-effectiveness ratio.

Vedolizumab SC is cost effective compared with conventional therapy based on a threshold of $50,000/quality-adjusted life-years in the anti-tumor necrosis factor-naïve patients.